Equate Maximum Strength Lidocaine Pain Relieving Patches Recalled for Manufacturing Deviations
Equate Maximum Strength Lidocaine Pain Relieving Patches (4%) are being recalled due to current Good Manufacturing Practice deviations. Approximately 1.1 million patches were distributed nationwide in the US.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall with no reported illnesses or injuries. The recall addresses manufacturing process deviations rather than a documented product defect with evidence of consumer harm.
Plain-English summary
Equate Maximum Strength Lidocaine Pain Relieving Patches containing 4% lidocaine are subject to recall due to manufacturing quality deviations at the production facility. The recalled product includes 1,101,600 patches distributed nationwide in the United States. The patches are sold in boxes of 6 and identified by NDC 79903-106-06 and UPC 681131071277.
Unexo Life Sciences Private Limited, the manufacturer, initiated this voluntary recall following identification of current Good Manufacturing Practice (cGMP) deviations. The FDA classified the recall as Class II. The company notified distributors by letter on October 24, 2024, and the recall was terminated on September 16, 2025.
The patches were distributed by Walmart Inc. nationwide in the United States. Consumers who possess this product should cease use and dispose of it or return it to the retailer. Consumers with questions about the recall should contact Walmart or their healthcare provider.
The recalled product
- Product
- EQUATE PAIN RELIEVING PATCHES (LIDOCAINE 4%)
- Brand
- EQUATE PAIN RELIEVING PATCHES
- Manufacturer
- Unexo Life Sciences Private Limited
- Category
- Drug — Topical Anesthetic
- Hazard
- quality-control-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- UPC 6 81131 07127 7
UPCs (1)
- 681131071277
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27